Background: Drug resistance has become a major concern for antiviral therapy in patients with chronic hepatitis B (CHB), leading to an increased risk of treatment failure. We aimed to identify the prevalence of hepatitis B virus (HBV) DNA polymerase mutations and to determine the frequency of HBV genotypes and subgenotypes in treatment-naive patients with CHB in Mekong Delta, Vietnam.Methods: Of the 550 drug-naive CHB patients from Mekong Delta, their serum samples were analyzed for HBV DNA mutations, genotypes, and subgenotypes using polymerase chain reaction sequencing.Results: Of the 550 patients who were infected with either HBV genotype B (72.9%) or genotype C (27.1%), the frequencies of subgenotypes were 19% B1, 3.6% B2, 10.3% B3, 39.8% B4, 0.4% C1, and 26.9% C2. The only mutation that was detected in 54 patients (10.7%) was rtV207M. The rtV207M mutation was found among 13.9% (51/368) of genotype B and among 2.2% (3/137) of genotype C (P < 0.0001).Discussion: Genotype B and subgenotype B4 are predominant in Mekong Delta. Only 1 mutation rtV207M is discovered in our study. These findings suggest that it is unnecessary to test for HBV resistance mutation before delivering antiviral therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.